Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. We sought to determine the relationships between: (a) trait hope, expectation of symptom benefit from chemotherapy, and anxiety and depression; (b) hope and perceived efficacy of chemotherapy; and (c)...
Main Authors: | Sjoquist, K, Friedlander, M, O'Connell, R, Voysey, M, King, M, Stockler, MR, Oza, A, Gillies, K, Martyn, J, Butow, P |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
2013
|
פריטים דומים
-
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
מאת: Friedlander, M, et al.
יצא לאור: (2014) -
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
מאת: King, M, et al.
יצא לאור: (2014) -
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
מאת: Marina Bagnoli, et al.
יצא לאור: (2019-02-01) -
Will patients benefit from regionalization of gynecologic cancer care?
מאת: Kathleen F Brookfield, et al.
יצא לאור: (2009-01-01) -
Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers
מאת: Tibor A. Zwimpfer, et al.
יצא לאור: (2024-01-01)